drugset / Trial / NCT04010877
Multiple CAR-T Cell Therapy Targeting AML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and refractory AML. The study also aims to learn more about the function of CAR T cells and their persistency in AML patients.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2028-07-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | — | Intravenous |